CLINICAL TRIALS PROFILE FOR ALOGLIPTIN BENZOATE
✉ Email this page to a colleague
All Clinical Trials for alogliptin benzoate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01990300 ↗ | Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus | Completed | Takeda | 2011-11-28 | The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride | |
| NCT02756832 ↗ | An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2 | Completed | Takeda | 2016-09-20 | The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6. | |
| NCT02856113 ↗ | Phase 3 Alogliptin Pediatric Study | Active, not recruiting | Takeda Development Center Americas, Inc. | Phase 3 | 2016-11-28 | The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM). |
| NCT02856113 ↗ | Phase 3 Alogliptin Pediatric Study | Active, not recruiting | Takeda | Phase 3 | 2016-11-28 | The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM). |
| NCT03499704 ↗ | A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy | Recruiting | Celltrion Pharm, Inc. | Phase 4 | 2020-02-11 | The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52. |
| NCT03499704 ↗ | A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy | Recruiting | Takeda | Phase 4 | 2020-02-11 | The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin (HbA1c) change from baseline at Week 52. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for alogliptin benzoate
Condition Name
Clinical Trial Locations for alogliptin benzoate
Trials by Country
Clinical Trial Progress for alogliptin benzoate
Clinical Trial Phase
Clinical Trial Sponsors for alogliptin benzoate
Sponsor Name
